Replies to post #3040 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

There is some new data from the phase 3 ensitrelvir study.

https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/presentation/2024/1q/E_FY2024_1Q%20financial%20result.pdf

dewophile, that link doesn't work.

[DewDiligence]

PFE increased [2024 full-year] Paxlovid guidance by 500M to 3.5B.

This is a pretty bug surprise, IMO, as it implies 2H24 Paxlovid revenues of about $1.2B.

See #msg-174835917 for more info on PFE's 2Q24 results and full-year guidance.